Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Ambra Spolverini"'
Autor:
Ambra Spolverini, Lisa Pieri, Paola Guglielmelli, Alessandro Pancrazzi, Tiziana Fanelli, Chiara Paoli, Alberto Bosi, Ilaria Nichele, Marco Ruggeri, Alessandro M. Vannucchi
Publikováno v:
Haematologica, Vol 98, Iss 9 (2013)
Externí odkaz:
https://doaj.org/article/69169de1d1d54c73a5be21140e110dad
Publikováno v:
Oncogene
Monoubiquitylation of histone H2B (H2Bub1) is catalyzed mainly by the RNF20/RNF40 complex and erased by multiple deubiquitylating enzymes (DUBs). H2Bub1 influences many aspects of chromatin function, including transcription regulation and DNA repair.
Autor:
Ayalew Tefferi, Flavia Biamonte, Nc Cross, G Barosi, Rp Ketterling, Andreas Reiter, Rossella Manfredini, Lisa Pieri, Mc Susini, Enrico Tagliafico, Christy Finke, Ambra Spolverini, Naseema Gangat, Elisa Rumi, Roberta Zini, Tl Lasho, Katerina Zoi, Giada Rotunno, Andrew S Duncombe, Alessandro Pancrazzi, Animesh Pardanani, Carmela Mannarelli, Rr Laborde, Alessandro M. Vannucchi, Daniela Pietra, Amy V. Jones, Ra Knudson, Paola Guglielmelli, Francisco Cervantes, Arturo Pereira, Joannah Score, Mario Cazzola
Publikováno v:
Leukemia. 27:1861-1869
Patient outcome in primary myelofibrosis (PMF) is significantly influenced by karyotype. We studied 879 PMF patients to determine the individual and combinatorial prognostic relevance of somatic mutations. Analysis was performed in 483 European patie
Autor:
A Isgrò, Giovanni Barosi, Lisa Pieri, Alessandro M. Vannucchi, Flavia Biamonte, Paola Guglielmelli, Alberto Bosi, Alessandro Pancrazzi, Ambra Spolverini, Elisabetta Antonioli
Publikováno v:
Leukemia. 24:1533-1537
Autor:
Gaetano Bergamaschi, Paolo Catarsi, Vittorio Rosti, Valentina Poletto, Massimo Primignani, Adriana Carolei, Alessandro M. Vannucchi, Laura Villani, Ambra Spolverini, Giovanni Barosi
Publikováno v:
Leukemia Research. 36:e7-e9
1Unit of Clinical Epidemiology and Center for the Study of Myelofibrosis, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy 2Department of Internal Medicine, Unit of Clinica Medica 1, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy 3Gastroent
Autor:
Carmela Mannarelli, Katerina Zoi, Paola Guglielmelli, Giovanni Barosi, Francisco Cervantes, Ambra Spolverini, Alessandro M. Vannucchi, Maria Chiara Susini, Andreas Reiter, Mario Cazzola, Flavia Biamonte, Andrew S Duncombe, Nicholas C.P. Cross
Publikováno v:
British journal of haematology. 162(3)
Autor:
Ambra Spolverini, Umberto Occhini, Silvia Birtolo, Lisa Pieri, Barbara Scappini, Francesco Albano, Alberto Bosi, Carmen Fava, Alessandro M. Vannucchi
Publikováno v:
Blood. 118(12)
Progression of chronic myelogenous leukemia (CML) to accelerated (AP) and blast phase (BP) is because of secondary molecular events, as well as additional cytogenetic abnormalities. On the basis of the detection of JAK2, CBL, CBLB, TET2, ASXL1, and I
Autor:
Amy V. Jones, Ambra Spolverini, Nicholas C.P. Cross, Lisa Pieri, Alessandro M. Vannucchi, Andreas Hochhaus
Publikováno v:
Annals of hematology. 90(3)
Dear Editor, Philadelphia-chromosome negative chronic myeloproliferative neoplasms (MPNs) include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis [1]. In 2005, a point mutation in JAK2 (JAK2V617F) was shown to occur
Autor:
Alessandro Pancrazzi, Alessandro M. Vannucchi, Paola Guglielmelli, Ilaria Nichele, Lisa Pieri, Marco Ruggeri, Alberto Bosi, Chiara Paoli, Tiziana Fanelli, Ambra Spolverini
Publikováno v:
Haematologica. 98:e101-e102
LNK (SH2B3) belongs to a family of adaptor proteins that contain a proline-rich N-terminal dimerization domain, a pleckstrin homology domain (PH), an Src homology-2 domain (SH2), and a conserved C-terminal tyrosine residue. By binding to cytokine rec
Autor:
Paola Guglielmelli, J. Score, Mario Cazzola, G Barosi, Flavia Biamonte, Elisa Rumi, Katerina Zoi, Carmela Mannarelli, Andrew S Duncombe, Daniela Pietra, Alessandro M. Vannucchi, Ambra Spolverini, Alberto Bosi, Maria Chiara Susini, Alessandro Pancrazzi, Amy V. Jones, Giada Rotunno, Andreas Reiter, Francisco Cervantes, Arturo Pereira, Nicholas C.P. Cross
Publikováno v:
Blood. 120:431-431
Abstract 431 Background. Primary myelofibrosis (PMF) has the worst prognosis among myeloproliferative neoplasms with median overall survival (OS) of 4.6y in the International Prognostic Scoring System (IPSS) series (Cervantes F, Blood 2009;113:2895)